北欧国家奥密克戎流行期异源第三剂疫苗方案比较有效性
该研究基于丹麦、芬兰、挪威和瑞典的队列分析,纳入至少接种过AZD1222或mRNA基础免疫程序的成人,比较异源加强针与基础程序及同源mRNA加强针在奥密克戎流行期的疫苗有效性。结果显示,异源加强针对新冠相关住院和死亡的保护优于仅基础程序,且相比同源mRNA加强针对住院有额外保护。
要点
- 异源加强针对住院有效性82.7%和81.5%,对死亡95.9%和87.5%。
- 同源mRNA加强针对住院有效性≥76.5%,对死亡≥84.1%。
- 异源相比同源加强针对住院有效性27.2%和23.3%。
核心结论
- 异源加强针方案相比基础程序及同源mRNA加强针,与更高的奥密克戎相关重症covid-19保护相关。
研究设计与样本
- 基于人群的队列分析,覆盖丹麦、芬兰、挪威和瑞典,2020年12月27日至2022年12月31日。
- 纳入≥18岁、至少接受过AZD1222或mRNA基础程序(任意组合)的成人。
- 比较异源加强针与基础程序(匹配分析)及与同源mRNA加强针(加权分析),随访加强针后14天起75天。
主要发现
- 相比仅基础程序,AZD1222+BNT162b2或mRNA-1273异源加强针对住院有效性82.7%(95%CI 77.1%至88.2%),对死亡95.9%(91.6%至100.0%)。
- 相比仅基础程序,BNT162b2+mRNA-1273异源加强针对住院有效性81.5%(78.9%至84.2%),对死亡87.5%(82.5%至92.6%)。
- 同源mRNA加强针相比仅基础程序,对住院有效性≥76.5%,对死亡≥84.1%。
- 异源相比同源加强针,AZD1222+BNT162b2或mRNA-1273对住院有效性27.2%(3.7%至50.6%),BNT162b2+mRNA-1273对住院有效性23.3%(15.8%至30.8%)。
- 异源相比同源加强针对死亡有效性:AZD1222+BNT162b2或mRNA-1273为21.7%(-8.3%至51.7%),BNT162b2+mRNA-1273为18.4%(-15.7%至52.5%)。
临床怎么用
- 在奥密克戎流行期,对已完成基础免疫的成人,可考虑异源加强针以增强对重症covid-19的保护。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
OBJECTIVE: To investigate the comparative vaccine effectiveness of heterologous booster schedules (ie, three vaccine doses) compared with primary schedules (two vaccine doses) and with homologous mRNA vaccine booster schedules (three vaccine doses) during a period of omicron predominance. DESIGN: Population based cohort analyses. SETTING: Denmark, Finland, Norway, and Sweden, 27 December 2020 to 31 December 2022. PARTICIPANTS: All adults aged ≥18 years who had received at least a primary vaccination schedule of AZD1222 (Oxford-AstraZeneca) or monovalent SARS-CoV-2 wild type (ancestral) strain based mRNA vaccines BNT162b2 (Pfizer-BioNTech) or mRNA-1273 (Moderna), in any combination. MAIN OUTCOME MEASURES: The main outcome measure was country combined risks of covid-19 related hospital admission and death with covid-19 and additional outcomes of covid-19 related admission to an intensive care unit and SARS-CoV-2 infection. During a period of omicron predominance, these outcomes were compared in those who received a heterologous booster versus primary schedule (matched analyses) and versus those who received a homologous mRNA vaccine booster (weighted analyses). Follow-up was for 75 days from day 14 after the booster dose; comparative vaccine effectiveness was calculated as 1-risk ratio. RESULTS: Across the four Nordic countries, 1 086 418 participants had received a heterologous booster schedule of AZD1222+BNT162b2 or mRNA-1273 and 2 505 093 had received a heterologous booster schedule of BNT162b2+mRNA-1273. Compared with the primary schedule only (two doses), the vaccine effectiveness of heterologous booster schedules comprising AZD1222+BNT162b2 or mRNA-1273 and BNT162b2+mRNA-1273 was 82.7% (95% confidence interval 77.1% to 88.2%) and 81.5% (78.9% to 84.2%) for covid-19 related hospital admission and 95.9% (91.6% to 100.0%) and 87.5% (82.5% to 92.6%) for death with covid-19, respectively. Homologous mRNA booster schedules were similarly associated with increased protection against covid-19 related hospital admission (≥76.5%) and death with covid-19 (≥84.1%) compared with previous primary course vaccination only. When a heterologous booster schedule was compared with the homologous booster schedule, vaccine effectiveness was 27.2% (3.7% to 50.6%) for AZD1222+BNT162b2 or mRNA-1273 and 23.3% (15.8% to 30.8%) for BNT162b2+mRNA-1273 schedules against covid-19 related hospital admission and 21.7% (-8.3% to 51.7%) and 18.4% (-15.7% to 52.5%) against death with covid-19, respectively. CONCLUSION: Heterologous booster schedules are associated with increased protection against severe, omicron related covid-19 outcomes compared with primary course schedules and homologous booster schedules.
引用
- Andersson NW, Thiesson EM, Baum U, et al. Comparative effectiveness of heterologous third dose vaccine schedules against severe covid-19 during omicron predominance in Nordic countries: population based cohort analyses. BMJ. 2023. PMID: 37487623. doi:10.1136/bmj-2022-074325
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。